Mariner LLC Buys 840 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Mariner LLC boosted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 42.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,825 shares of the company's stock after acquiring an additional 840 shares during the period. Mariner LLC's holdings in Medpace were worth $939,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Barclays PLC lifted its holdings in shares of Medpace by 42.4% during the 4th quarter. Barclays PLC now owns 28,166 shares of the company's stock valued at $9,359,000 after purchasing an additional 8,385 shares in the last quarter. Giverny Capital Inc. lifted its stake in Medpace by 3.2% in the fourth quarter. Giverny Capital Inc. now owns 234,287 shares of the company's stock valued at $77,837,000 after buying an additional 7,215 shares in the last quarter. Townsquare Capital LLC boosted its holdings in shares of Medpace by 7.0% in the fourth quarter. Townsquare Capital LLC now owns 12,387 shares of the company's stock valued at $4,115,000 after buying an additional 806 shares during the period. Distillate Capital Partners LLC increased its position in shares of Medpace by 2.7% during the fourth quarter. Distillate Capital Partners LLC now owns 44,317 shares of the company's stock worth $14,723,000 after acquiring an additional 1,155 shares in the last quarter. Finally, Grandeur Peak Global Advisors LLC raised its holdings in shares of Medpace by 0.6% during the fourth quarter. Grandeur Peak Global Advisors LLC now owns 28,265 shares of the company's stock worth $9,390,000 after acquiring an additional 165 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Stock Performance

NASDAQ:MEDP traded up $4.91 during mid-day trading on Friday, hitting $307.16. The stock had a trading volume of 72,428 shares, compared to its average volume of 341,192. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $459.77. The stock has a market cap of $8.83 billion, a price-to-earnings ratio of 24.21, a PEG ratio of 3.81 and a beta of 1.46. The company's 50 day simple moving average is $310.62 and its 200 day simple moving average is $330.57.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, beating analysts' consensus estimates of $3.06 by $0.61. Medpace had a return on equity of 51.48% and a net margin of 19.17%. The business had revenue of $558.57 million for the quarter, compared to analysts' expectations of $528.38 million. During the same quarter in the prior year, the business earned $3.20 EPS. As a group, equities analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Insider Buying and Selling at Medpace

In other Medpace news, Director Fred B. Davenport, Jr. sold 1,712 shares of the stock in a transaction on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total transaction of $516,715.84. Following the transaction, the director now owns 2,998 shares in the company, valued at $904,856.36. This trade represents a 36.35 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 20.30% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on MEDP shares. Robert W. Baird reduced their target price on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a research note on Wednesday, April 23rd. William Blair reaffirmed a "market perform" rating on shares of Medpace in a research report on Tuesday, April 22nd. Leerink Partners initiated coverage on Medpace in a research report on Monday, March 24th. They issued a "market perform" rating and a $330.00 target price on the stock. Leerink Partnrs raised Medpace to a "hold" rating in a research report on Monday, March 24th. Finally, Mizuho lowered their price objective on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a report on Wednesday, April 9th. Eleven analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $349.30.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.